Pulmatrix, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Peter B. Ludlum
- Full Time Employees
- 2
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 945 Concord Street Framingham MA United States 01701
- IPO Date
- Mar 21, 2014
- CIK
- 0001574235
- Website
- pulmatrix.com
- Similar Companies
- Business
- Pulmatrix, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel inhaled therapeutic products designed to prevent and treat migraine and respiratory diseases using its proprietary dry powder delivery technology, iSPERSE™. The company's core product pipeline includes PUR3100, a Phase 2-ready acute migraine treatment; PUR1800 for acute exacerbations of chronic obstructive pulmonary disease (AECOPD); and PUR1900 targeting allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma and cystic fibrosis. Pulmatrix's iSPERSE technology enables the formulation of small, dense, and dispersible particles to optimize drug delivery for deep lung penetration, aiming to improve pharmacokinetics and reduce systemic side effects. The company operates primarily in the United States and focuses on therapies for serious pulmonary and central nervous system disorders. Founded in 2005, Pulmatrix is headquartered in Lexington, Massachusetts. Recent major developments include a proposed merger agreement with Cullgen Inc., a clinical-stage biopharmaceutical company focused on targeted protein degrader therapies for cancer and pain. This merger, anticipated to close in the first half of 2025, aims to create a Nasdaq-listed entity combining Pulmatrix's inhalation platform with Cullgen's uSMITE™ platform for targeted protein degradation. As part of the merger strategy, Pulmatrix plans to divest its proprietary dry powder delivery assets, including its investigational migraine product PUR3100 and other candidates based on the iSPERSE technology. In 2025, Pulmatrix also completed wind-down activities for PUR1900 and closed licensing transactions for its iSPERSE technology with MannKind Corporation. The company amended its partnership with Cipla, which assumed development of PUR1900 outside the U.S., and focused on maximizing shareholder value through strategic alternatives while maintaining a cash runway into late 2026. Pulmatrix's business segments encompass developing inhaled therapeutics for respiratory diseases and migraine treatment, targeting patient populations with unmet medical needs. The company's strategic focus shifting through divestment and merger plans reflects its transformation towards an integrated biopharmaceutical entity advancing novel therapies in targeted protein degradation alongside inhalation therapeutics. Pulmatrix continues to prioritize advancing clinical-stage assets and expanding its technology platform collaboration footprint to optimize therapeutic outcomes for serious diseases.
Company News
Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse
Pulmatrix (NASDAQ:PULM) Share Price Breaks Below Fifty Day Moving Average – Here’s What Happened
Pulmatrix, Inc. (NASDAQ:PULM) Stock Short Interest Rises 174.2%
Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--PULM, SLP, OLN, and HUN
Pulmatrix Announces First Quarter 2026 Financial Results
Pulmatrix Announces First Quarter 2026 Financial Results
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders
Pulmatrix (NASDAQ:PULM) Share Price Crosses Below Fifty Day Moving Average – Should You Sell?
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results
Pulmatrix (NASDAQ:PULM) Share Price Crosses Below 50 Day Moving Average – What’s Next?
INmune Bio (NASDAQ:INMB) & Pulmatrix (NASDAQ:PULM) Head-To-Head Review
Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
Pulmatrix (NASDAQ:PULM) Stock Price Passes Below 50-Day Moving Average – Here’s Why
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
Pulmatrix (PULM) Q2 Revenue Falls 100%